In 2019-2020 Osler successfully represented Teva Canada in a judicial review application brought by Novo Nordisk Canada Inc. in respect of a decision of the Minister of Health concerning Teva’s drug submission for liraglutide. The application was struck, providing a major victory for the generic industry as Teva resisted brand interference in review of its drug submission.
Teva Canada is a pharmaceutical company specializing in developing and producing generic medicines with a portfolio of 3,500 products in each therapeutic area.
Osler, Hoskin & Harcourt LLP advised Teva Canada with a team consisting of Brad White, Nathaniel Lipkus, Faylene Lunn and Lillian Wallace (Intellectual Property).